Biopharmaceutical innovation and world class R&DNSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.The NSB product portfolio includes several therapeutic peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II.
EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.
NSB Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held
